Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. (NASDAQ: OM) is a medical technology company focused on transforming dialysis with its Tablo Hemodialysis System, and its news flow reflects both business performance and developments in kidney care. Company press releases regularly describe Outset as pioneering a first-of-its-kind technology designed to reduce the cost and complexity of dialysis across hospital and home settings.
News updates for OM commonly include quarterly financial results, where Outset reports product revenue from Tablo consoles, recurring revenue from Tablo consumables and services, gross margin trends, operating expenses, and cash balances. These releases may also include revised or updated annual revenue guidance and commentary on progress toward financial objectives.
Investors and clinicians following Outset Medical can also expect clinical and research news. The company has highlighted data from large numbers of Tablo treatments across hundreds of facilities, as well as multi-year results from hospitals that have insourced dialysis service lines using Tablo. Such announcements focus on clinical outcomes, operational metrics, and the implications of insourced dialysis models for acute-care facilities.
Outset’s news stream further covers strategic and corporate developments, such as board appointments, the creation of clinical leadership roles, and collaborations with dialysis providers to expand access to home hemodialysis using Tablo. The company also announces presentations at major healthcare and investor conferences, where management discusses its technology, business strategy, and financial performance.
This OM news page aggregates these releases so readers can follow Outset Medical’s earnings reports, clinical evidence updates, collaborations, and corporate milestones in one place.
Outset Medical reported a remarkable 33.3% revenue growth in Q1 2022, reaching $30.6 million compared to $22.9 million in Q1 2021. Gross margin improved significantly to 14.5%, up from 1.3% the previous year. The company achieved a product revenue increase of 40.9% to $25.7 million. Despite these positive metrics, the net loss grew to $36.9 million or ($0.78) per share. Full-year revenue guidance now ranges from $144 million to $150 million, suggesting continued strong growth momentum.
Outset Medical, Inc. (Nasdaq: OM) will present at the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 12:00 PM PT / 3:00 PM ET. This event will showcase their innovative Tablo Hemodialysis System, designed to reduce costs and complexities in dialysis treatment. An archived webcast will be available on the company’s website. The Tablo system represents a significant advancement in dialysis care, enabling treatment anywhere and anytime, enhancing patient experience and provider efficiency.
Outset Medical, Inc. (NASDAQ: OM) has appointed Dale E. Jones to its Board of Directors, effective immediately. With over 30 years of experience in team building and human capital issues, Jones aims to contribute to Outset's growth in the medical technology sector. His previous roles include Senior Advisor at Diversified Search Group and CEO for over eight years. Outset's flagship product, the Tablo Hemodialysis System, simplifies dialysis for patients and providers, highlighting the company's commitment to innovation in healthcare.
Outset Medical, Inc. (NASDAQ: OM) will release its first quarter 2022 financial results on May 4, 2022, after market close. A conference call, led by CEO Leslie Trigg and CFO Nabeel Ahmed, is scheduled for 2:00 PM PT (5:00 PM ET) on the same day to discuss these results. The company specializes in innovative dialysis solutions, particularly the FDA-cleared Tablo® Hemodialysis System, which simplifies dialysis processes and improves patient care.
Outset Medical, Inc. (NASDAQ: OM) reported new data on its Tablo Hemodialysis System at the 2022 NKF Spring Clinical Meetings in Boston. A national survey showed that 72% of dialysis patients believe Tablo offers significant clinical improvements, while 77% would consider home hemodialysis. Additionally, 77% of nephrologists view Tablo as superior to existing devices, with 98% inclined to recommend it to patients. The costs associated with peritoneal dialysis (PD) failure can exceed $72,000 per patient in hospitalization, highlighting the potential cost benefits of transitioning to home hemodialysis sooner.
Outset Medical, Inc. (Nasdaq: OM), a leader in medical technology, will participate in a fireside chat at the 42nd Annual Cowen Health Care Conference on March 8, 2022, at 11:50 AM PT. This event will provide insights into their groundbreaking Tablo Hemodialysis System, designed to simplify dialysis and reduce costs. A live and archived webcast will be available on the Outset Medical website. Tablo allows for dialysis to be administered easily across various settings, transforming patient care and operational efficiency.
Outset Medical, Inc. (Nasdaq: OM) reported record annual revenue of $102.6 million for 2021, marking a 105.5% year-over-year growth. The fourth quarter revenue reached $28.2 million, up 63.2% from the previous year. The company achieved a gross margin of 11.8% in Q4, improving significantly from 2.4% in Q4 2020. Operating expenses for 2021 were $138.1 million, with a net loss of ($131.9 million). Looking ahead, Outset projects revenue for 2022 between $142 million and $150 million, indicating further growth.
Outset Medical, Inc. (Nasdaq: OM) announced management participation in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 18, 2022, at 12:40pm PT / 3:40pm ET. The event will be accessible via a live and archived webcast on Outset's website. Outset Medical is revolutionizing dialysis with its Tablo Hemodialysis System, which simplifies treatment and reduces costs. This FDA-cleared technology enables delivery of dialysis anywhere by utilizing integrated water purification and on-demand dialysate production.
Outset Medical, Inc. (Nasdaq: OM) will announce its financial results for Q4 and the full year of 2021 after market close on February 16, 2022. A conference call will follow at 2:00 PM PT (5:00 PM ET), led by CEO Leslie Trigg and CFO Nabeel Ahmed. The call can be accessed by dialing specific numbers for domestic and international callers. Outset's Tablo® Hemodialysis System aims to simplify dialysis with its innovative technology, making treatment accessible and efficient across various settings.
Outset Medical, Inc. (NASDAQ: OM) has received FDA clearance for a new sterilization method of the Tablo Hemodialysis System cartridge. This advancement allows production to shift to North America, particularly Mexico, which is expected to reduce costs and enhance supply chain reliability. The new method is eco-friendly, utilizing e-beam technology. CEO Leslie Trigg highlighted that this milestone aims to improve gross margins while addressing manufacturing challenges and logistics.